Lagoutte-Renosi Jennifer, Allemand Florentin, Ramseyer Christophe, Yesylevskyy Semen, Davani Siamak
EA 3920 Université Bourgogne Franche-Comté, 25000 Besançon, France; Laboratoire de Pharmacologie Clinique et Toxicologie-CHU de Besançon, 25000 Besançon, France.
EA 3920 Université Bourgogne Franche-Comté, 25000 Besançon, France; Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, 25000 Besançon, France.
Drug Discov Today. 2022 Apr;27(4):985-1007. doi: 10.1016/j.drudis.2021.11.026. Epub 2021 Dec 1.
Molecular modeling in pharmacology is a promising emerging tool for exploring drug interactions with cellular components. Recent advances in molecular simulations, big data analysis, and artificial intelligence (AI) have opened new opportunities for rationalizing drug interactions with their pharmacological targets. Despite the obvious utility and increasing impact of computational approaches, their development is not progressing at the same speed in different fields of pharmacology. Here, we review current in silico techniques used in cardiovascular diseases (CVDs), cardiological drug discovery, and assessment of cardiotoxicity. In silico techniques are paving the way to a new era in cardiovascular medicine, but their use somewhat lags behind that in other fields.
药理学中的分子建模是一种很有前景的新兴工具,用于探索药物与细胞成分的相互作用。分子模拟、大数据分析和人工智能(AI)的最新进展为阐明药物与其药理学靶点的相互作用带来了新机遇。尽管计算方法具有明显的实用性且影响力不断增加,但其在药理学不同领域的发展速度并不相同。在此,我们综述了目前用于心血管疾病(CVD)、心脏病药物研发和心脏毒性评估的计算机模拟技术。计算机模拟技术正在为心血管医学的新时代铺平道路,但其应用在一定程度上落后于其他领域。